Oral neratinib: Interim Ph II CONTROL data

Interim data from 135 patients with early stage HER2-positive breast cancer who previously completed Herceptin trastuzumab-based adjuvant therapy in the open-label, international Phase II CONTROL trial showed that the rate of grade 3 diarrhea in patients who

Read the full 378 word article

User Sign In